氨氯地平联合瑞伐他汀对高血压合并高血脂患者疗效评价
|
摘要
目的探讨氨氯地平联合瑞舒伐他汀对高血压合并高血脂患者疗效。方法选取自2017年1月至2018年1月武警湖北总队医院收治的高血压合并高血脂患者643例作为研究对象。按照用药不同分为A、B两组,A组,硝苯地平联合瑞舒伐他汀;B组,氨氯地平联合瑞舒伐他汀。观察两组患者6个月的治疗效果;两组患者治疗前后血压、血脂、心、肝和肾功能情况;两组患者治疗前和治疗后6个月并发症发生率比较。结果治疗后6个月,A组患者总有效率为82.0%(297/362)低于B组95.7%(269/281);两组患者治疗后血压、血脂和心功能得到改善,但肝功能和肾功能受损;但B组血压、血脂和心功能改善优于A组,肝功能和肾功能受损低于A组,差异具有统计学意义(P<0.05)。治疗后6个月,A组患者内并发症发生率36.2%(131/362)高于B组24.2%(68/281),差异具有统计学意义(P<0.05)。结论氨氯地平联合瑞舒伐他汀具有更佳的降压、降脂效果,具有更小的心、肝和肾毒性,更低的不良事件发生率,值得推广。
Objective To investigate the effect of amlodipine combined with rosuvastatin on patients with hypertension and hyperlipidemia. Method 643 patients with hypertension and hyperlipidemia admitted to Hubei General Team Hospital of Armed Police Force from January 2017 to January 2018 were selected as the study subjects. The patients were divided into group A, nifedipine combined with rosuvastatin, and group B, amlodipine combined with rosuvastatin.The treatment effect of the two groups was observed for 6 months. The blood pressure, blood lipid, heart, liver and kidney function of the two groups before and after treatment were observed. The incidence of complications was compared between the two groups before and after treatment for 6 months. Result Six months after treatment, the total effective rate of group A was 82.0%(297/362) lower than that of group B 95.7%(269/281). After treatment,blood pressure, blood lipid and cardiac function were improved, but liver function and renal function were impaired.However, the improvement of blood pressure, blood lipid and cardiac function in group B was better than that in group A, and the impairment of liver function and renal function was lower than that in group A(P < 0.05). Six months after treatment, the incidence of complications in group A was 36.2%(131/362) higher than that in group B(24.2%(68/281),the difference was statistically significant(P < 0.05). Conclusion Amlodipine combined with rosuvastatin has better antihypertensive and lipid-lowering effects, less cardiotoxicity, liver and kidney toxicity, and lower incidence of adverse events, which is worthy of promotion.
Objective To investigate the effect of amlodipine combined with rosuvastatin on patients with hypertension and hyperlipidemia. Method 643 patients with hypertension and hyperlipidemia admitted to Hubei General Team Hospital of Armed Police Force from January 2017 to January 2018 were selected as the study subjects. The patients were divided into group A, nifedipine combined with rosuvastatin, and group B, amlodipine combined with rosuvastatin.The treatment effect of the two groups was observed for 6 months. The blood pressure, blood lipid, heart, liver and kidney function of the two groups before and after treatment were observed. The incidence of complications was compared between the two groups before and after treatment for 6 months. Result Six months after treatment, the total effective rate of group A was 82.0%(297/362) lower than that of group B 95.7%(269/281). After treatment,blood pressure, blood lipid and cardiac function were improved, but liver function and renal function were impaired.However, the improvement of blood pressure, blood lipid and cardiac function in group B was better than that in group A, and the impairment of liver function and renal function was lower than that in group A(P < 0.05). Six months after treatment, the incidence of complications in group A was 36.2%(131/362) higher than that in group B(24.2%(68/281),the difference was statistically significant(P < 0.05). Conclusion Amlodipine combined with rosuvastatin has better antihypertensive and lipid-lowering effects, less cardiotoxicity, liver and kidney toxicity, and lower incidence of adverse events, which is worthy of promotion.
引文
[1]Behr J,Ryu J H.Pulmonary hypertension in interstitial lung disease[M]//Diffuse Lung Disease.2017.
[2]Chiang GSH,Sim BLH,Lee JJM,et al.Determinants of poor sleep quality in elderly patients with diabetes mellitus,hyperlipidemia and hypertension in Singapore[J].Prim Health Care Res Dev,2018,19(6):610-615.
[3]Yilmaz B,Vellanki P,Ata B,et al.Metabolic syndrome,hypertension,and hyperlipidemia in mothers,fathers,sisters,and brothers of women with polycystic ovary syndrome:a systematic review and meta-analysis[J].Fertil Steril,2018,109(2):356-364.
[4]Cheng KH,Cheng KC,Cheng KY,et al.Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension:a nationwide cohort study[J].Curr Med Res Opin,2017,33(6):1111-1117.
[5]中国高血压防治指南起草委员会.中国高血压防治指南[J].中国卒中杂志,2006(8):575-582.
[6]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中国实用乡村医生杂志,2012,19(16):4-14.
[7]Accetto R,Chazova IY,Sirenko Y,et al.The efficacy and safety of valsartan and the combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension-the VICTORY trial[J].Kardiol Pol,2017,75(1):55-64.
[8]王宝华,王海燕,王娟,等.应用超声背向散射积分评价高脂血症患者颈动脉粥样硬化[J].吉林大学学报(医学版),2006,32(5):923-925.
[9]Fan YC,Hsu JL,Tung HY,et al.Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia:a population-based cohort study[J].Alzheimers Res Ther,2017,9(1):7.
[10]Henry PD.Comparative pharmacology of calcium antagonists:nifedipine,verapamil and diltiazem[J].Am JCardiol,1980,46(6):1047-1058.
[11]刘淑涛,王慧玲,娄鹏举,等.硝苯地平和氨氯地平治疗高血压疗效与安全性的Meta分析[J].中国药房,2011,22(16):1494-1497.
[12]周嬿.左旋氨氯地平联合瑞舒伐他汀治疗高血压并高血脂探讨[J].中国继续医学教育,2018,10(32):128-131.
[13]Schils E.Lipid-lowering therapy in the elderly[J].Rev Med Brux,2017,38(4):363-365.
[14]左莉莉,张旭刚,苏辉,等.阿托伐他汀钙联合硝苯地平缓释片治疗老年高血压合并心律失常的疗效及对肝肾功能影响[J].中国地方病防治杂志,2017,32(3):327-329.
[15]刘福颂,任晓兰,李成建.硝苯地平不良反应[J].中国误诊学杂志,2009,9(18):4526-4527.
[2]Chiang GSH,Sim BLH,Lee JJM,et al.Determinants of poor sleep quality in elderly patients with diabetes mellitus,hyperlipidemia and hypertension in Singapore[J].Prim Health Care Res Dev,2018,19(6):610-615.
[3]Yilmaz B,Vellanki P,Ata B,et al.Metabolic syndrome,hypertension,and hyperlipidemia in mothers,fathers,sisters,and brothers of women with polycystic ovary syndrome:a systematic review and meta-analysis[J].Fertil Steril,2018,109(2):356-364.
[4]Cheng KH,Cheng KC,Cheng KY,et al.Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension:a nationwide cohort study[J].Curr Med Res Opin,2017,33(6):1111-1117.
[5]中国高血压防治指南起草委员会.中国高血压防治指南[J].中国卒中杂志,2006(8):575-582.
[6]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中国实用乡村医生杂志,2012,19(16):4-14.
[7]Accetto R,Chazova IY,Sirenko Y,et al.The efficacy and safety of valsartan and the combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension-the VICTORY trial[J].Kardiol Pol,2017,75(1):55-64.
[8]王宝华,王海燕,王娟,等.应用超声背向散射积分评价高脂血症患者颈动脉粥样硬化[J].吉林大学学报(医学版),2006,32(5):923-925.
[9]Fan YC,Hsu JL,Tung HY,et al.Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia:a population-based cohort study[J].Alzheimers Res Ther,2017,9(1):7.
[10]Henry PD.Comparative pharmacology of calcium antagonists:nifedipine,verapamil and diltiazem[J].Am JCardiol,1980,46(6):1047-1058.
[11]刘淑涛,王慧玲,娄鹏举,等.硝苯地平和氨氯地平治疗高血压疗效与安全性的Meta分析[J].中国药房,2011,22(16):1494-1497.
[12]周嬿.左旋氨氯地平联合瑞舒伐他汀治疗高血压并高血脂探讨[J].中国继续医学教育,2018,10(32):128-131.
[13]Schils E.Lipid-lowering therapy in the elderly[J].Rev Med Brux,2017,38(4):363-365.
[14]左莉莉,张旭刚,苏辉,等.阿托伐他汀钙联合硝苯地平缓释片治疗老年高血压合并心律失常的疗效及对肝肾功能影响[J].中国地方病防治杂志,2017,32(3):327-329.
[15]刘福颂,任晓兰,李成建.硝苯地平不良反应[J].中国误诊学杂志,2009,9(18):4526-4527.